Burning Rock
AI-powered oncology genomics platform for liquid biopsy, tumor profiling, and precision medicine decision support.
What it does
Burning Rock is an AI-native precision oncology company that combines genomic sequencing technology with AI interpretation - providing liquid biopsy (blood-based cancer detection), tumor tissue profiling, and AI-powered treatment decision support for oncologists. Its AI capabilities include machine learning algorithms that detect circulating tumor DNA from blood samples at low allele frequencies, AI-powered variant classification that interprets genetic mutations and their clinical significance for treatment selection, and treatment matching algorithms that align tumor mutation profiles to FDA-approved therapies and clinical trials. Burning Rock serves oncologists at cancer centers and hospitals who need molecular profiling to guide precision oncology treatment decisions - particularly immunotherapy and targeted therapy selection.
Why AI-NATIVE
Burning Rock is AI-native - machine learning detection of circulating tumor DNA from sequencing data, AI variant classification, and treatment matching algorithms are the core scientific platform capabilities.
Best for
Cancer centers, hospital oncology programs, and pharmaceutical companies use Burning Rock for precision oncology - AI liquid biopsy enabling early detection and treatment response monitoring, and AI tumor profiling informing targeted therapy selection.
Limitations
Genomic testing reimbursement is complex and varies by payer, indication, and geographic market — organizations must understand coverage and reimbursement dynamics before deploying liquid biopsy programs at scale.
Burning Rock's AI provides variant classification and treatment matching but oncologists must integrate findings with clinical context — molecular tumor boards and genetic counselors are important partners for complex cases.
Burning Rock is a leading oncology genomics company in China with an expanding US presence — organizations outside its established markets should evaluate service coverage, turnaround time, and regulatory status for their specific geography.
Alternatives by segment
| If you need… | Consider instead |
|---|---|
| US-focused comprehensive genomic profiling | Guardant Health |
| Oncology precision medicine platform | Tempus |
| Clinical trial matching for oncology | Antidote Technologies |
Burning Rock genomic tests priced per test, varying by panel scope and sample type. Liquid biopsy panels typically $2,000 to $5,000 per test. Enterprise contracts for high-volume cancer center programs. Reimbursement coverage varies by payer.
